Evidence map›Paper›PMID 35200527›Full record

ArticleGeriatrics (Basel, Switzerland)2022

Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review.

Cid Ould Ouali, Nadia Ladjouzi, Khidher Tamas, Hendriniaina Raveloson, Jihene Ben Hassen, Nesrine El Omeiri, Georges Zouloumis, Mohamed Moataz Al Zoabi, Muneer Asadi, Aziza Jhouri and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Geriatrics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Cid Ould OualiDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Nadia LadjouziDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Khidher TamasDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Hendriniaina RavelosonDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Jihene Ben HassenDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Nesrine El OmeiriDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Georges ZouloumisDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Mohamed Moataz Al ZoabiDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Muneer AsadiDepartment of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Aziza JhouriPharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Joël SchlatterPharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.ORCID 0000-0002-4443-8843
Assistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tocilizumab treatment could be a potential therapeutic option for old patients. We report the case of an 88-year-old man with COVID-19 disease who presented at the admission with anemia, fever, oxygen desaturation (92%), and inflammatory syndrome (C-reactive protein (CRP) at 182.5 mg/L; reference range <5.0 mg/L). After remaining CRP level increase (206.6 mg/L), Tocilizumab administration led to rapid clinical outcome and resolution of his inflammatory syndrome. This case report represents a supplementary data confirming the efficacy and safety of Tocilizumab for COVID-19 in elderly patients.

Indexed as

case reportCOVID-19elderlyinflammatory syndromeTocilizumab

Identifiers

PMID35200527
PMCPMC8872498
OpenAlexW4213138858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.